Biopool Seeks Federal OK for Protein C Test
- Share via
Biopool International in Ventura is seeking Food and Drug Administration approval for its test to determine sensitivity to activated protein C.
APC resistance is a genetic defect that is the leading cause of clot-forming diseases that affect nearly 25 million people in the United States and Europe.
“Assuming only 10% of those affected by thrombophilia have an episode requiring diagnostic work-up, the potential market for this product could be approximately $10 million per year,” said Michael D. Bick, chairman and chief executive officer. “At present, there is only one other comparable product on the market.”
Biopool manufactures test kits to assess and diagnose blood disorders.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
